Hinge Health, Inc. Class A (HNGE) Stock Forecast & Price Target

Compare

151 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HNGE Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Hinge

Health, Inc. Class A

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HNGE Stock 12 Month Forecast

Average Price Target

$67.53

▲(35.63% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Hinge Health, Inc. Class A in the last 3 months. The average price target is $67.53 with a high forecast of $90.00 and a low forecast of $59.00. The average price target represents a 35.63% change from the last price of $49.79.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"$39","52":"$52","65":"$65","78":"$78","91":"$91"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":59,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$59.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,52,65,78,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.96,51.19384615384615,54.42769230769231,57.66153846153846,60.895384615384614,64.12923076923077,67.36307692307693,70.59692307692308,73.83076923076923,77.0646153846154,80.29846153846154,83.53230769230768,86.76615384615386,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.96,49.465384615384615,50.97076923076923,52.47615384615385,53.98153846153846,55.48692307692308,56.99230769230769,58.497692307692304,60.003076923076925,61.50846153846154,63.01384615384615,64.51923076923077,66.02461538461539,{"y":67.53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.96,48.80923076923077,49.65846153846154,50.50769230769231,51.356923076923074,52.206153846153846,53.05538461538462,53.90461538461538,54.753846153846155,55.60307692307693,56.45230769230769,57.30153846153846,58.15076923076923,{"y":59,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.16,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.16,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.45,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.68,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$90.00

Average Price Target$67.53

Lowest Price Target$59.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jailendra Singh

Truist Financial

―

Buy

―

Reiterated

12/11/25

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Exelixis (NASDAQ: EXEL) and Natera (NASDAQ: NTRA)

David Grossman

Stifel Nicolaus

$64.29

Buy

29.12%

Upside

Reiterated

11/14/25

Hinge Health, Inc. Class A (HNGE) Gets a Buy from Stifel Nicolaus

Craig Hettenbach

Morgan Stanley

$72

Buy

44.61%

Upside

Assigned

11/10/25

Buy Rating on Hinge Health, Inc.: Attractive Valuation and Strong Financial Position Amid Market Concerns

Richard Close

Canaccord Genuity

$61→$65

Buy

30.55%

Upside

Reiterated

11/05/25

Hinge Health price target raised to $65 from $61 at CanaccordHinge Health price target raised to $65 from $61 at Canaccord

Bradley Sills

Bank of America Securities

$64

Buy

28.54%

Upside

Reiterated

11/05/25

Bank of America Securities Sticks to Its Buy Rating for Hinge Health, Inc. Class A (HNGE)

Elizabeth Anderson CFA

Evercore ISI

$65

Buy

30.55%

Upside

Reiterated

11/05/25

Evercore ISI Reaffirms Their Buy Rating on Hinge Health, Inc. Class A (HNGE)

Ryan MacDonald

Needham

$59

Buy

18.50%

Upside

Reiterated

11/05/25

Needham Remains a Buy on Hinge Health, Inc. Class A (HNGE)

Jessica Tassan

Piper Sandler

$70→$71

Buy

42.60%

Upside

Reiterated

11/05/25

Hinge Health price target raised to $71 from $70 at Piper SandlerHinge Health price target raised to $71 from $70 at Piper Sandler

Ryan Daniels

William Blair

―

Buy

―

Reiterated

11/04/25

Hinge Health: Strong Financial Performance and Growth Potential Amidst Rising Demand for Digital MSK Solutions

Rishi Jaluria

RBC Capital

$60

Buy

20.51%

Upside

Reiterated

11/04/25

RBC Capital Sticks to Its Buy Rating for Hinge Health, Inc. Class A (HNGE)

Saket Kalia

Barclays

$51→$90

Buy

80.76%

Upside

Reiterated

11/03/25

Barclays Remains a Buy on Hinge Health, Inc. Class A (HNGE)

Aaron Kimson

Citizens JMP

$65

Buy

30.55%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Bicycle Therapeutics (NASDAQ: BCYC) and Foghorn Therapeutics (NASDAQ: FHTX)

Vikram Kesavabhotla

Robert W. Baird

$56

Hold

12.47%

Upside

Initiated

09/04/25

Hinge Health initiated with a Neutral at BairdHinge Health initiated with a Neutral at Baird

Brian Peterson

Raymond James

$45→$65

Buy

30.55%

Upside

Reiterated

08/06/25

Hinge Health price target raised to $65 from $45 at Raymond JamesHinge Health price target raised to $65 from $45 at Raymond James

Scott Schoenhaus

KeyBanc

$45

Buy

-9.62%

Downside

Initiated

06/16/25

Hinge Health, Inc. Class A (HNGE) Gets a Buy from KeyBanc

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jailendra Singh

Truist Financial

―

Buy

―

Reiterated

12/11/25

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Exelixis (NASDAQ: EXEL) and Natera (NASDAQ: NTRA)

David Grossman

Stifel Nicolaus

$64.29

Buy

29.12%

Upside

Reiterated

11/14/25

Hinge Health, Inc. Class A (HNGE) Gets a Buy from Stifel Nicolaus

Craig Hettenbach

Morgan Stanley

$72

Buy

44.61%

Upside

Assigned

11/10/25

Buy Rating on Hinge Health, Inc.: Attractive Valuation and Strong Financial Position Amid Market Concerns

Richard Close

Canaccord Genuity

$61→$65

Buy

30.55%

Upside

Reiterated

11/05/25

Hinge Health price target raised to $65 from $61 at CanaccordHinge Health price target raised to $65 from $61 at Canaccord

Bradley Sills

Bank of America Securities

$64

Buy

28.54%

Upside

Reiterated

11/05/25

Bank of America Securities Sticks to Its Buy Rating for Hinge Health, Inc. Class A (HNGE)

Elizabeth Anderson CFA

Evercore ISI

$65

Buy

30.55%

Upside

Reiterated

11/05/25

Evercore ISI Reaffirms Their Buy Rating on Hinge Health, Inc. Class A (HNGE)

Ryan MacDonald

Needham

$59

Buy

18.50%

Upside

Reiterated

11/05/25

Needham Remains a Buy on Hinge Health, Inc. Class A (HNGE)

Jessica Tassan

Piper Sandler

$70→$71

Buy

42.60%

Upside

Reiterated

11/05/25

Hinge Health price target raised to $71 from $70 at Piper SandlerHinge Health price target raised to $71 from $70 at Piper Sandler

Ryan Daniels

William Blair

―

Buy

―

Reiterated

11/04/25

Hinge Health: Strong Financial Performance and Growth Potential Amidst Rising Demand for Digital MSK Solutions

Rishi Jaluria

RBC Capital

$60

Buy

20.51%

Upside

Reiterated

11/04/25

RBC Capital Sticks to Its Buy Rating for Hinge Health, Inc. Class A (HNGE)

Saket Kalia

Barclays

$51→$90

Buy

80.76%

Upside

Reiterated

11/03/25

Barclays Remains a Buy on Hinge Health, Inc. Class A (HNGE)

Aaron Kimson

Citizens JMP

$65

Buy

30.55%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Bicycle Therapeutics (NASDAQ: BCYC) and Foghorn Therapeutics (NASDAQ: FHTX)

Vikram Kesavabhotla

Robert W. Baird

$56

Hold

12.47%

Upside

Initiated

09/04/25

Hinge Health initiated with a Neutral at BairdHinge Health initiated with a Neutral at Baird

Brian Peterson

Raymond James

$45→$65

Buy

30.55%

Upside

Reiterated

08/06/25

Hinge Health price target raised to $65 from $45 at Raymond JamesHinge Health price target raised to $65 from $45 at Raymond James

Scott Schoenhaus

KeyBanc

$45

Buy

-9.62%

Downside

Initiated

06/16/25

Hinge Health, Inc. Class A (HNGE) Gets a Buy from KeyBanc

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hinge Health, Inc. Class A

1 Month

xxx

Success Rate

3/4 ratings generated profit

Average Return

+16.40%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +16.40% per trade.

3 Months

xxx

Success Rate

3/4 ratings generated profit

Average Return

+20.90%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +20.90% per trade.

1 Year

Saket KaliaBarclays

Success Rate

3/4 ratings generated profit

Average Return

+11.43%

reiterated a buy rating last month

Copying Saket Kalia's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +11.43% per trade.

2 Years

xxx

Success Rate

3/4 ratings generated profit

Average Return

+11.43%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +11.43% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HNGE Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HNGE has received 22 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. HNGE average Analyst price target in the past 3 months is 67.53.

Each month's total comprises the sum of three months' worth of ratings.

HNGE Financial Forecast

HNGE Earnings Forecast

Next quarter’s earnings estimate for HNGE is $0.41 with a range of $0.40 to $0.44. The previous quarter’s EPS was $0.42. HNGE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year HNGE has Performed in-line its overall industry.

HNGE Sales Forecast

Next quarter’s sales forecast for HNGE is $156.82M with a range of $155.94M to $163.00M. The previous quarter’s sales results were $154.21M. HNGE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year HNGE has Performed in-line its overall industry.

HNGE Stock Forecast FAQ

What is HNGE’s average 12-month price target, according to analysts?

Based on analyst ratings, Hinge Health, Inc. Class A’s 12-month average price target is 67.53.

What is HNGE’s upside potential, based on the analysts’ average price target?

Hinge Health, Inc. Class A has 35.63% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HNGE a Buy, Sell or Hold?

Hinge Health, Inc. Class A has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Hinge Health, Inc. Class A’s price target?

The average price target for Hinge Health, Inc. Class A is 67.53. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $90.00 ,the lowest forecast is $59.00. The average price target represents 35.63% Increase from the current price of $49.79.

What do analysts say about Hinge Health, Inc. Class A?

Hinge Health, Inc. Class A’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of HNGE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Hinge Health, Inc. Class A (HNGE) Stock Forecast & Price Target

HNGE Analyst Ratings

HNGE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hinge Health, Inc. Class A

HNGE Analyst Recommendation Trends

HNGE Financial Forecast

HNGE Earnings Forecast

HNGE Sales Forecast

HNGE Stock Forecast FAQ

Detailed List of Analyst Forecasts